Q3 Earnings Estimate for CLDX Issued By HC Wainwright

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Research analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Celldex Therapeutics in a research report issued to clients and investors on Thursday, February 26th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will earn ($1.33) per share for the quarter. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. HC Wainwright also issued estimates for Celldex Therapeutics’ Q4 2026 earnings at ($1.38) EPS and FY2026 earnings at ($5.28) EPS.

Several other analysts have also recently issued reports on CLDX. Barclays upped their price objective on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, January 21st. Finally, Stifel Nicolaus reissued a “buy” rating and set a $68.00 price objective (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Celldex Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $44.20.

Celldex Therapeutics Stock Down 1.8%

Celldex Therapeutics stock opened at $30.09 on Monday. The company has a fifty day simple moving average of $25.70 and a 200-day simple moving average of $25.52. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of -7.74 and a beta of 1.17. Celldex Therapeutics has a 52-week low of $14.40 and a 52-week high of $31.31.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The firm had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $1.53 million. Celldex Therapeutics had a negative return on equity of 41.67% and a negative net margin of 3,446.88%.

Institutional Investors Weigh In On Celldex Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Celldex Therapeutics by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after acquiring an additional 680 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Celldex Therapeutics by 327.3% during the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock valued at $7,259,000 after buying an additional 306,330 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Celldex Therapeutics by 12.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock worth $2,383,000 after purchasing an additional 14,979 shares during the last quarter. AlphaQuest LLC raised its stake in shares of Celldex Therapeutics by 7.0% in the 2nd quarter. AlphaQuest LLC now owns 12,956 shares of the biopharmaceutical company’s stock valued at $264,000 after purchasing an additional 844 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in shares of Celldex Therapeutics by 171.7% during the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 881 shares during the last quarter.

Key Stories Impacting Celldex Therapeutics

Here are the key news stories impacting Celldex Therapeutics this week:

• Positive Sentiment: New Phase 2 clinical data for barzolvolimab presented at AAAAI show sustained off‑treatment efficacy in chronic spontaneous urticaria (CSU) and meaningful quality‑of‑life gains in cold urticaria/symptomatic dermographism — potential upside for future regulatory/label discussions and commercial prospects. Celldex Presents Additional Positive Data
• Positive Sentiment: Analyst bullishness: Stifel reaffirmed a Buy and raised its price target to $68, and Morgan Stanley reiterated a Buy — these upgrades/support increase the stock’s upside narrative for investors focused on clinical catalysts. Stifel Reaffirms Buy, Raises PT
• Positive Sentiment: Sell‑side coverage remains constructive overall (average rating around “Moderate Buy”), which can sustain interest into upcoming 2026 data readouts and EMBARQ enrollment updates. TipRanks / Analyst Note
• Neutral Sentiment: HC Wainwright published EPS forecasts for FY2026/FY2027 (negative EPS expected), providing modeling detail but no change in clinical outlook; useful for valuation but not an immediate catalyst. HC Wainwright Estimates (MarketBeat)
• Neutral Sentiment: Mixed media and analyst commentary (Beaumont Enterprise, AmericanBankingNews) reinforce analyst interest but do not add new clinical or financial surprises. Q4 Snapshot
• Negative Sentiment: Recent Q4 2025 financials disappointed: the company missed EPS and revenue expectations, reported very large negative margins and negative ROE, and consensus still expects meaningful losses for 2026 — headwinds for near‑term sentiment and valuation. Q4 and Year‑End 2025 Results
• Negative Sentiment: Short interest data posted recently are inconsistent/odd (reported as zero), which may create temporary noise but reflects no clear short‑pressure signal.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.